Reducing skin toxicities from egfr inhibitors with topical braf inhibitor therapy

Mario E. Lacouture, Zev A. Wainberg, Anisha B. Patel, Milan J. Anadkat, Salomon M. Stemmer, Einat Shacham-Shmueli, Egmidio Medina, Galit Zelinger, Noa Shelach, Antoni Ribas

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human skin keratinocytes. We then conducted a phase I clinical trial testing the hypothesis that topical therapy with the BRAF inhibitor LUT014 could improve skin toxicities induced by EGFR inhibitors. Ten patients with metastatic colorectal cancer who had developed acneiform rash while being treated with cetuximab or panitumumab were enrolled in three cohorts. LUT014 was well tolerated, and there were no doselimiting toxicities. The acneiform rash improved in the 6 patients who started with grade 2 rash in the low and intermediate cohorts. We conclude that topical LUT014 is safe and efficacious in improving rash from EGFR inhibitors, consistent with the mechanism of action inducting paradoxical MAPK activation. Significance: BRAF inhibitor topical therapy could avoid dose reductions of EGFR inhibitors, locally treating the main dose-limiting skin toxicity of this class of agents.

Original languageEnglish
Pages (from-to)2158-2167
Number of pages10
JournalCancer discovery
Issue number9
StatePublished - Sep 2021


Dive into the research topics of 'Reducing skin toxicities from egfr inhibitors with topical braf inhibitor therapy'. Together they form a unique fingerprint.

Cite this